Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03106779 · OUTCOME

Major Molecular Response (MMR) Rate at All Scheduled Data Collection Time Points Except Weeks 24 & 96

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · Source last updated 2026-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
at Weeks 36, 48, 60, 72, 84, 108, 120, 132, 144 & 156

What was measured

MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.

Analysis population: Full Analysis Set (FAS): The FAS comprised of all randomized participants.

Groups in this outcome

Asciminib

Participants randomized to asciminib 40mg BID

Bosutinib

Participants randomized to bosutinib 500mg QD

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Asciminib157
Bosutinib76

Reported measurements

at Week 36
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Asciminib41Not reportedNot reportedNot reportedNot reported
Bosutinib9Not reportedNot reportedNot reportedNot reported
at Week 48
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Asciminib46Not reportedNot reportedNot reportedNot reported
Bosutinib10Not reportedNot reportedNot reportedNot reported
at Week 60
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Asciminib52Not reportedNot reportedNot reportedNot reported
Bosutinib11Not reportedNot reportedNot reportedNot reported
at Week 72
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Asciminib52Not reportedNot reportedNot reportedNot reported
Bosutinib12Not reportedNot reportedNot reportedNot reported
at Week 84
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Asciminib50Not reportedNot reportedNot reportedNot reported
Bosutinib10Not reportedNot reportedNot reportedNot reported
at Week 108
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Asciminib53Not reportedNot reportedNot reportedNot reported
Bosutinib11Not reportedNot reportedNot reportedNot reported
at Week 120
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Asciminib57Not reportedNot reportedNot reportedNot reported
Bosutinib8Not reportedNot reportedNot reportedNot reported
at Week 132
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Asciminib58Not reportedNot reportedNot reportedNot reported
Bosutinib8Not reportedNot reportedNot reportedNot reported
at Week 144
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Asciminib59Not reportedNot reportedNot reportedNot reported
Bosutinib7Not reportedNot reportedNot reportedNot reported
at Week 156
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Asciminib53Not reportedNot reportedNot reportedNot reported
Bosutinib8Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        41
      2. group Id
        OG001
        value
        9
    title
    at Week 36
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        46
      2. group Id
        OG001
        value
        10
    title
    at Week 48
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        52
      2. group Id
        OG001
        value
        11
    title
    at Week 60
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        52
      2. group Id
        OG001
        value
        12
    title
    at Week 72
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        50
      2. group Id
        OG001
        value
        10
    title
    at Week 84
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        53
      2. group Id
        OG001
        value
        11
    title
    at Week 108
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        57
      2. group Id
        OG001
        value
        8
    title
    at Week 120
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        58
      2. group Id
        OG001
        value
        8
    title
    at Week 132
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        59
      2. group Id
        OG001
        value
        7
    title
    at Week 144
  10. categories
    1. measurements
      1. group Id
        OG000
        value
        53
      2. group Id
        OG001
        value
        8
    title
    at Week 156
denoms
  1. counts
    1. group Id
      OG000
      value
      157
    2. group Id
      OG001
      value
      76
    units
    Participants
description
MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.
groups
  1. description
    Participants randomized to asciminib 40mg BID
    id
    OG000
    title
    Asciminib
  2. description
    Participants randomized to bosutinib 500mg QD
    id
    OG001
    title
    Bosutinib
param Type
COUNT_OF_PARTICIPANTS
population Description
Full Analysis Set (FAS): The FAS comprised of all randomized participants.
reporting Status
POSTED
time Frame
at Weeks 36, 48, 60, 72, 84, 108, 120, 132, 144 & 156
title
Major Molecular Response (MMR) Rate at All Scheduled Data Collection Time Points Except Weeks 24 & 96
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice